Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takayuki Nakashima is active.

Publication


Featured researches published by Takayuki Nakashima.


Clinical Cancer Research | 2010

New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

Takayuki Nakashima; Toshihiko Ishii; Hisashi Tagaya; Toshihiro Seike; Hiroshi Nakagawa; Yutaka Kanda; Shiro Akinaga; Shiro Soga; Yukimasa Shiotsu

Purpose: The heat shock protein 90 (Hsp90) plays an important role in chaperoning oncogenic client proteins in multiple myeloma (MM) cells, and several Hsp90 inhibitors have shown antitumor activities both in vitro and in vivo. However the precise mechanism of action of Hsp90 inhibitor in MM has not been fully elucidated. Experimental Design: We evaluated the antitumor activities of KW-2478, a nonansamycin Hsp90 inhibitor, in MM cells with various chromosomal translocations of immunoglobulin heavy chain (IgH) loci both in vitro and in vivo. Results: Our studies revealed that exposure of KW-2478 to MM cells resulted in growth inhibition and apoptosis, which were associated with degradation of well-known client proteins as well as a decrease in IgH translocation products (FGFR3, c-Maf, and cyclin D1), and FGFR3 was shown to be a new client protein of Hsp90 chaperon complex. In addition, KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor. Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression. In NCI-H929 s.c. inoculated model, KW-2478 showed a significant suppression of tumor growth and induced the degradation of client proteins in tumors. Furthermore, in a novel orthotopic MM model of i.v. inoculated OPM-2/green fluorescent protein, KW-2478 showed a significant reduction of both serum M protein and MM tumor burden in the bone marrow. Conclusions: These results suggest that targeting such diverse pathways by KW-2478 could be a promising strategy for the treatment of MM with various cytogenetic abnormalities. Clin Cancer Res; 16(10); 2792–802. ©2010 AACR.


Bioorganic & Medicinal Chemistry Letters | 2001

Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions

Masami Kaneko; Takayuki Nakashima; Yuko Uosaki; Mitsunobu Hara; Shun-ichi Ikeda; Yutaka Kanda

Tetrocarcin A was recently identified as an inhibitor of the anti-apoptotic function of Bcl-2. We synthesized novel tetrocarcin derivatives in order to increase their selective inhibitory activity against Bcl-2. It was found that 21-acetoxy-9-glycosyloxy derivatives had potent Bcl-2 inhibitory activity without significant antimicrobial activity.


Bioorganic & Medicinal Chemistry Letters | 2008

Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.

Hideyuki Onodera; Masami Kaneko; Yuichi Takahashi; Yumiko Uochi; Jun Funahashi; Takayuki Nakashima; Shiro Soga; Makoto Suzuki; Shun-ichi Ikeda; Yoshinori Yamashita; Endang S. Rahayu; Yutaka Kanda; Michio Ichimura

Hsp90 is an attractive chemotherapeutic target because it is essential to maturation of multiple oncogenes. We describe the conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin isolated from Streptomyces sp. Their native free structures are similar to the active form of geldanamycin bound to Hsp90 protein. Their conformational character is a probable reason for their high-affinity binding. Lack of toxic benzoquinone in EH21A1-A4 also adds to their potential as lead compounds for anti-tumor drugs.


Archive | 2004

Hsp90 family protein inhibitors

Shinji Nara; Hiroshi Nakagawa; Yutaka Kyowa Hakko Kogyo Co. Ltd. Kanda; Takayuki Nakashima; Shiro Soga; Jiro Kajita; Jun-ichi Kyowa Hakko Kogyo Co. Ltd. Saito; Yukimasa Shiotsu; Shiro Kyowa Hakko Kogyo Co. Ltd. Akinaga


Archive | 2006

Benzenoid ansamycin derivative

Shinpei Yamaguchi; Takayuki Nakashima; Yutaka Kanda


Archive | 2001

Agent for inducing apoptosis

Mitsunobu Hara; Takayuki Nakashima; Yutaka Kanda; Masami Hamano; Shun-ichi Ikeda; Yuko Uosaki; Yoko Takata; Junji Kanazawa


Blood | 2008

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Jüliger; Takayuki Nakashima; Lenushka Maharaj; Toshihiko Ishii; Hiroshi Nakagawa; Yutaka Kanda; Heather Oakervee; J Cavenagh; Shiro Akinaga; Yukimasa Shiotsu; Simon Joel


Cancer Research | 2010

Abstract 2636: Preclinical evaluation of the Hsp90 inhibitor KW-2478 in combination with bortezomib as a treatment for multiple myeloma

Toshihiko Ishii; Takayuki Nakashima; Toshihiro Seike; Aiko Shudo; Shiro Akinaga; Shiro Soga; Yukimasa Shiotsu


Archive | 2008

Therapeutic agent for cancer with resistance to protease inhibitor

Takayuki Nakashima; Yukimasa Shiotsu


Archive | 2008

Agent thérapeutique pour le cancer avec une résistance à l'inhibiteur de la protéase

Takayuki Nakashima; Yukimasa Shiotsu

Collaboration


Dive into the Takayuki Nakashima's collaboration.

Top Co-Authors

Avatar

Yutaka Kanda

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Shiro Soga

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge